SpringWorks Therapeutics
  • Become A SpringWorker
  • |
  • Contact Us
  • |
  • LinkedIn
  • |
  • Twitter
  • Who We Are
    • Overview
    • Our Values
    • Leadership
    • Board of Directors
  • Patients & Families
    • Overview
    • Desmoid Tumors
    • Neurofibromatosis
      Type 1
    • Expanded Access
  • Pipeline
    • Overview
    • Nirogacestat
    • Mirdametinib
    • Investigator Initiated Research
  • Clinical Trials
    • Overview
    • DeFi Trial
    • ReNeu Trial
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Investor Contacts
      • Email Alerts
  • Partnering
    • Overview
    • Our Collaborators

Leadership

Saqib Islam, J.D.

Saqib Islam, J.D.

Chief Executive Officer
Francis Perier, Jr.

Francis Perier, Jr.

Chief Financial Officer
Stephen Squinto, Ph.D.

Stephen Squinto, Ph.D.

Acting Head of Research and Development
Jens Renstrup, M.D., MBA

Jens Renstrup, M.D., MBA

Chief Medical Officer
Badreddin Edris, Ph.D.

Badreddin Edris, Ph.D.

Chief Operating Officer
L. Mary Smith, Ph.D.

L. Mary Smith, Ph.D.

Chief Development Officer
Herschel S. Weinstein, J.D.

Herschel S. Weinstein, J.D.

General Counsel and Secretary
Daniel Pichl

Daniel Pichl

Chief People Officer

Saqib Islam, J.D.

Chief Executive Officer
Saqib Islam, J.D.

Saqib Islam was appointed chief executive officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as chief financial officer and chief business officer. Prior to joining SpringWorks Therapeutics, Saqib was chief business officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to joining Moderna, Saqib served as executive vice president, chief strategy and portfolio officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Board of Directors of Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options.

Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.

Francis Perier, Jr.

Chief Financial Officer
Francis Perier, Jr.

Frank Perier is Chief Financial Officer of SpringWorks. He was previously Chief Financial Officer at Forest Laboratories, Inc. for ten years prior to the company’s acquisition by Actavis. Prior to joining Forest, Mr. Perier was with Bristol-Myers Squibb Company for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning – Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Mr. Perier was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company.

Mr. Perier received a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Science in Accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.

Stephen Squinto, Ph.D.

Acting Head of Research and Development
Stephen Squinto, Ph.D.

Stephen Squinto, Ph.D., joined SpringWorks Therapeutics at launch in 2017 and is acting head of research and development. Steve is a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was a co-founder of Alexion Pharmaceuticals and recently served as its executive vice president and chief global operations officer. Prior to 2013, he was Alexion’s global head of research and development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Steve received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.

Jens Renstrup, M.D., MBA

Chief Medical Officer
Jens Renstrup, M.D., MBA

Dr. Jens Renstrup is responsible for developing and driving execution of the clinical development programs and oversees medical affairs. Prior to joining SpringWorks Therapeutics, Jens was senior vice president and head of global medical affairs at Alexion Pharmaceuticals, where he helped to shape the company’s early- to late-stage development pipeline and was instrumental in building out a leading medical affairs function. Prior to Alexion, Jens served as vice president and head of global medical affairs at Glaxo Smith Kline Vaccines, where he developed the company’s medical strategy, which included evidence and engagement programs, and helped shape the development pipeline to support rapid drug applications in Europe, the United States and emerging markets. Jens also previously held progressive leadership positions at Merck & Co and started his career at IPSEN Scandinavia A/S.

Jens received a M.D. and specialist medical degree in anesthesiology and intensive care medicine from the University of Copenhagen, and an MBA from the Copenhagen Business School.

Badreddin Edris, Ph.D.

Chief Operating Officer
Badreddin Edris, Ph.D.

Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was chief business officer) and Edgewise Therapeutics (where he was chief operating officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.

Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.

L. Mary Smith, Ph.D.

Chief Development Officer
L. Mary Smith, Ph.D.

Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics, Mary was the executive vice president of gene therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was vice president of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology.

Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.

Herschel S. Weinstein, J.D.

General Counsel and Secretary
Herschel S. Weinstein, J.D.

Herschel Weinstein is General Counsel of SpringWorks. He was previously Vice Chair of the Life Sciences Group at Lowenstein Sandler LLP where he represented life sciences companies in licensing, acquisitions, collaborations and joint venture transactions. Prior to his role at Lowenstein, Mr. Weinstein was General Counsel of Forest Laboratories, Inc. for approximately eight years prior to the company’s acquisition by Actavis. While at Forest, Mr. Weinstein established the in-house legal function, was responsible for the significant licensing, collaboration and acquisition transactions that the company executed, served as Corporate Secretary for all Corporate Governance and Board matters, and provided legal support to all functions of the organization. Before joining Forest, Mr. Weinstein served as outside counsel for the company over many years as a partner at the law firm Dornbush Schaeffer Strongin & Venaglia, LLP.

Mr. Weinstein received a J.D. from Harvard Law School and a Bachelor of Arts from Brandeis University.

Daniel Pichl

Chief People Officer
Daniel Pichl

Daniel Pichl is an accomplished human resources executive who joined SpringWorks from Siemens Healthineers, USA where he was Senior Vice President, Head of Human Resources and Global HR Business Partner for the Ultrasound division. At Siemens, he had global responsibility for People Strategy, Employee Relations, Compensation & Benefits, Talent Acquisition, Talent & Performance Management, Leadership Development, and Learning. Prior to this role, he served as Vice President, Head of People & Leadership for the Americas region, and before that, he held positions of increasing responsibility at Siemens AG, Germany.

Mr. Pichl earned a Master of International Business degree from Macquarie University in Sydney, Australia, and a Master of Psychology degree from Ludwig-Maximilians-University in Munich, Germany.

SpringWorks Therapeutics
Who We Are
  • Overview
  • Our Values
  • Leadership
  • Board of Directors
Patients & Families
  • Overview
  • Desmoid Tumor
  • Neurofibromatosis
    Type 1
  • Expanded Access
Pipeline
  • Overview
  • Nirogacestat
  • Mirdametinib
  • Investigator Initiated Research
Clinical Trials
  • Overview
  • DeFi Trial
  • ReNeu Trial
Investors & Media
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Stock Information
  • Investor Resources
Partnering
  • Overview
  • Our Collaborators

© 2021 SpringWorks Therapeutics. All rights reserved. | Terms of Use | Privacy Policy

  • Become A SpringWorker
  • |
  • Contact Us
  • |
  • LinkedIn
  • |
  • Twitter

Swipe for More

Investigator-Initiated Research Terms and Conditions

All submitted proposals and related documents, including study concepts and protocols, shall be deemed Non-Confidential. No confidential relationship shall be established or implied by SpringWorks' acceptance of such materials.

SpringWorks shall have the right to retain any such materials. SpringWorks will only consider unsolicited IIR proposals submitted in writing by external investigators interested in studying SpringWorks drug candidates in therapeutic areas of interest. Support from SpringWorks, if any, will be granted on the basis of scientific merit. IIR budgets must be reasonable and appropriate for the proposed study.

Acceptance of the submission of a study concept or protocol does not constitute approval. SpringWorks reserves the right to decline support of a proposal any time after submission.

Following review by SpringWorks, the submitter will be notified as to whether the IIR proposal has been approved or denied, or if additional information is required. Approval of a study concept does not guarantee approval of a study protocol. SpringWorks shall have no obligation to give the reasons for its decisions.

SpringWorks support of an IIR will be subject to the execution of a written agreement which shall include terms aligned with the following principles:

  • Conduct of the Study. The IIR will be conducted in accordance with the final protocol as approved by SpringWorks, International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines, and all applicable governmental laws, rules, and regulations. Also, if study drug is supplied by SpringWorks as part of an IIR, the Institution is expected to follow SpringWorks instructions such as those regarding proper handling of study drug (e.g., storage and handling, expiration of drug notices, drug disposal or destruction).
  • Sponsorship. The Institution, not SpringWorks, will be the sponsor of the IIR. The Institution, the Principal Investigator and the Institution staff will not represent to any third party, including IIR subjects, that SpringWorks is a sponsor.
  • Regulatory. The Institution will be solely responsible for any and all safety reporting and regulatory obligations associated with the conduct of the IIR, including, but not limited to, obtaining and maintaining an Investigational New Drug application (IND), if required.
  • IRB/IACUC Approval. The Principal Investigator will ensure that the IIR is approved by and subject to continuing oversight by an appropriate Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC), and shall provide to SpringWorks a copy of such approval, and any extensions or renewals.
  • Informed Consent. For clinical studies, the Principal Investigator will obtain informed consent for each IIR subject in accordance with 21 Code of Federal Regulations Part 50 (unless an exemption under such part has been approved by the IRB and documentation of same can be provided), and will inform IIR subjects that SpringWorks is providing support for the IIR. SpringWorks shall have the right to review and comment on the informed consent form.
  • Registration of Study. For clinical studies, the Principal Investigator shall register the IIR at either (i)https://www.clinicaltrials.gov, or (ii) any other registry the requirements of which are consistent with the guidelines of the International Committee of Medical Journal Editors ("ICMJE") on trial registrations, in each case to the extent required by the ICMJE guidelines (as in effect at the time the IIR begins) in order for the IIR results to be eligible for publication in an ICMJE journal.
  • Reporting of Serious Adverse Events. For clinical studies utilizing a SpringWorks study drug product, within 24 hours of first awareness of the event (immediately if the event is fatal or life-threatening), the Principal Investigator will report to SpringWorks by email any Serious Adverse Event ("SAE") that occurs during the SAE reporting period (as defined in the agreement) in an IIR subject assigned to receive the SpringWorks study drug. The Principal Investigator will report to the appropriate Regulatory Authority (e.g., FDA) such SAEs using an FDA MEDWATCH form, and shall do so within the time frames set forth by FDA regulations. SAEs should be reported as soon as they are determined to meet the definition, even if complete information is not yet available.
  • Disclosure. SpringWorks will publicly disclose at its discretion, and in accordance with the information maintained in its internal business records, the name of the Institution and/or the Principal Investigator and certain information relating to the agreement including, but not limited to, any financial and in-kind payments received under the agreement, the nature of the engagement and any other payment or service-related information as may be deemed appropriate by SpringWorks or as may be dictated by applicable law. Payments to the Institution for work done by specified individuals may reference both the Institution and the individual.